Krystal Biotech, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $10.26B |
| Revenue | $417M |
| Net Income | $225M |
| Total Assets | $1.40B |
| Net Assets | $1.28B |
| Employees | 295 |
| Value | |
| P/E | 45.60x |
| P/B | 8.04x |
| PEG | 0.81x |
| P/S | 24.59x |
| EV/EBITDA | 52.64x |
| FCF Yield | 2.31% |
| Profitability | |
| ROE | 17.63% |
| ROA | 16.11% |
| Op. Margin | 42.85% |
| Revenue Growth | 31.95% |
| Earnings Growth | 56.53% |
| Financial Health | |
| Debt Ratio | 9.42% |
| Total Debt | $2M |
| FCF | $237M |
| Cash | $501M |
| Current Ratio | 9.46x |
| Net Debt/EBITDA | -2.69x |
| Performance | |
| 1Y Return | 163.50% |
| 1M Return | 18.67% |
| From 52W High | -2.37% |
| 1Y MDD | -29.83% |
| Trading | |
| Volume | 613,541 shares |
| Trading Value | $214M |
| Per Share | |
| EPS | $7.08 |
| BPS | $42.14 |
Company Info
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.